L3VLUP
ProSign in

UTHR · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

UTHRJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • UTHR
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterUTHRJNJ
Q3 202010 holders, $797m30 holders, $26.2bn
Q4 202011 holders, $1.2bn32 holders, $26.6bn
Q1 202110 holders, $1.4bn31 holders, $25.3bn
Q2 202111 holders, $1.5bn37 holders, $25.6bn
Q3 202116 holders, $1.5bn40 holders, $24.1bn
Q4 202114 holders, $1.9bn33 holders, $25.2bn
Q1 202214 holders, $1.7bn35 holders, $28.2bn
Q2 202218 holders, $2.3bn33 holders, $26.9bn
Q3 202217 holders, $2.2bn36 holders, $25.4bn
Q4 202218 holders, $2.9bn35 holders, $27.6bn
Q1 202316 holders, $2.5bn42 holders, $24.5bn
Q2 202312 holders, $2.5bn38 holders, $25.0bn
Q3 202313 holders, $2.4bn37 holders, $18.9bn
Q4 202314 holders, $2.3bn31 holders, $19.0bn
Q1 202419 holders, $2.2bn32 holders, $19.7bn
Q2 202414 holders, $2.5bn35 holders, $20.4bn
Q3 202410 holders, $2.9bn28 holders, $22.3bn
Q4 202414 holders, $3.3bn37 holders, $20.4bn
Q1 202514 holders, $2.1bn32 holders, $20.5bn
Q2 202514 holders, $1.9bn31 holders, $18.4bn
Q3 202516 holders, $2.6bn32 holders, $23.7bn
Q4 202514 holders, $3.8bn29 holders, $27.8bn
Q1 202618 holders, $5.1bn34 holders, $35.6bn
Q2 202614 holders, $3.5bn33 holders, $39.1bn
UTHR

United Therapeutics Corp Del

Holders
14
Reported value
$3.5bn
Buyers
19
Sellers
16

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only UTHR (5)

Baillie Gifford & Co, Point72 Asset Management LP, Renaissance Technologies LLC, Rokos Capital Management LLP, Winton Group Ltd

Only JNJ (24)

Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →